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Abstract 
Inhalation of fungal particles is a ubiquitous way of exposure to microorganisms during human life, however this 
exposure may promote or exacerbate respiratory diseases only in particular exposure conditions and human genetic 
background. Depending on the fungal species and form, fungal particles can induce symptoms in the lung by acting 
as irritants, aeroallergens or pathogens causing infection. Some thermophilic species, can even act in all these three 
ways (e.g. Aspergillus, Penicillium), mesophilic species being only involved in allergic and/or non-allergic airway 
diseases (e.g. Cladosporium, Alternaria, Fusarium). The goal of the present review is to present the current 
knowledge on the interaction between airborne fungal particles and the host immune system, to illustrate the 
differences of immune sensing of different fungal species and to emphasize the importance of conducting research 
on non-conventional mesophilic fungal species. Indeed, the diversity of fungal species we inhale and the complexity 
of their composition have a direct impact on fungal particle recognition and immune system decision to tolerate or 
respond to those particles, eventually leading to collateral damages promoting airway pathologies. 
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Fungal particles are ubiquitous in outdoor as well as in built environment air. Their growth is greatly dependent on 
humidity, temperature and availability of nutritive substrates. Fungal species can be present in aerosols in different 
forms: hyphae fragments, spores or yeast. Their number vary from thousand in the outdoor air [1], to forty in the 
indoor air [2]. The species composition in the air varies depending on the season [3] and on the presence of 
particular conditions of fungal growth (water-damage, waste, grain etc.). However, allergic and non-allergic 
respiratory diseases have been associated only to particular aerosols compositions [4-6] or to the presence of one 
dominant fungal species in the inhaled air [7]. Noteworthy, it was recently proposed that this is not the exposure to a 
particular fungal species that favors the development of respiratory pathologies, but the low diversity of the fungal 
species present in the inhaled air [8]. Yet, a large number of thermophilic as well as mesophilic fungal species have 
been incriminated in airway pathologies. The factors that favor growth of fungal species have been identified 
outdoor [7] and in the built environment [9], such as the occupational positions most likely at risk (manipulation of 
plant or animal derived products). The mechanisms underlying the development of allergic and non-allergic 
pathologies induced or exacerbated by fungi have been mostly explored for thermophilic species, rarely for 
mesophilic species. The goal of this review is to make a state of the art on the early events of host responses which 
impact on the resistance (restricting fungal burden) or tolerance (limiting collateral damages caused by the immune 
response) to fungi and to illustrate to which airway pathologies the disruption of host-fungus relationship may lead. 
We will first describe the coordinated action of airway resident cells to sense the dynamic structure of the fungal cell 
wall, made of polysaccharides (> 80%) and proteins, as well as fungal derived cytoplasmic and secreted compounds. 
Second, we will present the mechanisms involving fungi in the development of airway allergic disorders including 
allergic asthma, allergic bronchopulmonary aspergillosis (ABPA) and mycosis (ABPM), allergic fungal 
rhinosinusitis (AFRS) and hypersensitivity pneumonitis (HP) and airway non-allergic disorders such as chronic 
bronchitis, organic dust toxic syndrome and chronic mycotoxicosis. Of note, we will not discuss about chronic 
obstructive pulmonary disease (COPD) since no convincing association between COPD and airborne fungi has been 
reported despite the fact that 15 to 20% of non-smokers have an occupational exposure etiology and that the 
exposure to organic dust has been incriminated for some of them [10-12]. Finally, we will briefly discuss the genetic 
variants favoring the development of non-invasive fungal airway pathologies. 
1. Airway immune response to fungal compounds 
1.1. Processing of fungal particles in the airways 
Inhaled fungal particles deposit in different areas of the respiratory tract depending on their size, shape and 
aggregation with other substances. Large particles (over 5 μm) end in the nasopharyngeal region, whereas smaller 
particles may reach lung alveoli. Mucociliary clearance is the very first innate defense mechanism of the lung 
against the particles reaching the lung alveoli [13]. Cilia located along the airway walls provide a motive force for 
clearing microorganisms and toxic substances trapped in the mucus secreted by goblet cells. Moreover, mucus 
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contains an array of molecules with microbiocidal activity or that help neutralizing pathogens, among which β-
defensins, lyzosyme, lactoferrin, mucin, secretory IgA and surfactants.  
The immune response to fungi is influenced by fungal species, fungus form (spore, hyphae or yeast), fungus-derived 
products (such as mycotoxins and allergens), co-inhalation of fungus with other substances and host genetic 
background. The respiratory tract is a complex structure made of multiple structural epithelial cell types broadly 
classified into three categories (basal, ciliated and secretory cells) and infiltrated by leukocytes [14]. Besides 
phagocytic cells such as alveolar macrophages and dendritic cells (DCs) that reside in the airways or sense the 
airway lumen, epithelial cells and possibly mesenchymal cells play an active role in the initial events driving 
pulmonary immune responses. The cytokines and chemokines released following fungal contact by resident airway 
cells stimulate the recruitment and instruct innate and adaptive cells, among which neutrophils, eosinophils, 
basophils, mast cells, T cells and B cells. Other cells such as the recently identified lineage-negative innate 
lymphoid cells (ILCs) of subgroup 2 (ILC2) are central to fungal-induced allergic inflammation due to the 
production of interleukin (IL)-5 and IL-13 at early stage of allergen recognition [15, 16]. 
DCs are permanently trafficking from lungs to draining lymph nodes, a path presumably activated by subtle 
maturation signals provided by the local flora at steady state and strongly amplified in inflammatory conditions 
during which the cytokines released by the stroma or epithelial cells instruct DCs [17, 18]. DCs are particularly well 
equipped to decipher the fine structure of fungi, and the extreme plasticity of their response shapes the development 
of naïve CD4+ T cells into Th1, Th2 or Th17 cells that differentially affect antifungal responses [19]. For example, 
DCs exposed to Eurotium amstelodami or Wallemi sebi, two filamentous fungi involved in HP, induce a Th1 
polarized pathogenic response [20], whereas DCs exposed to Alternaria alternata, a common allergenic fungi 
responsible of asthma, trigger a potent Th2 skewed immune response [21].  
The differentiation of Th1, Th2 and Th17 cells is triggered by IL-12 and interferon (IFN) γ, IL-2 and IL-4 and IL-6, 
TGFβ, IL-21 and IL-23, respectively. Th1 responses are characterized by the production of IL-2 and IFNγ, which 
promote protective immunity against fungal infection through activation of phagocytes, antigen presentation by 
antigen presenting cells and production of opsonizing antibodies. IL-4, IL-5, IL-9, IL-10, IL-13, IL-25 and 
amphiregulin are the main drivers of Th2 cell responses that inhibit Th1 cell responses and promote alternative 
activation of macrophages, production of immunoglobulin (Ig) E, eosinophilia and mast cell growth resulting in 
decreased fungal clearance and favoring the development of fungal allergic responses. Th17 cells, characterized by 
the production of IL-17A, IL-17F, IL-21, IL-22, granulocyte-macrophage colony-stimulating factor (GM-CSF) and 
CC-chemokine ligand (CCL) 20, have been identified more recently as an additional subpopulation of CD4+ T cells 
involved in host defenses against extracellular microorganisms among which fungi [22, 23]. Th17 responses 
facilitate fungal clearance through the mobilization of neutrophils and the production of defensins. Th17 responses 
have also been implicated in the development of a number of autoimmune pathologies and in airway allergic 
diseases such as allergic rhinitis (AR) and chronic rhinosinusitis (CRS) [24]. 
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The immune response to fungi has to be tightly regulated to prevent inflammation-mediated collateral damage and 
maintain lung immune homeostasis. Pulmonary stromal cells promote transforming growth factor β (TGFβ)-
dependent generation of tolerogenic DCs that contribute to suppress T-cell proliferation through prostaglandin E2 
(PGE2) and induce the generation of regulatory (Treg) cells [25]. Treg cells produce high amounts of IL-10 and 
TGFβ that help limiting immunopathology, which in return may facilitate fungal persistence. 
1.2. Pathogen-associated molecular patterns and pattern-recognition receptors 
The fungal cell wall is mostly composed of polysaccharides (80-90%) and proteins, mostly glycoproteins. Pathogen-
associated molecular patterns (PAMPs) expressed by fungi are sensed by epithelial cells and sentinel phagocytic 
cells of the airways through pattern-recognition receptors (PRRs). The principal fungal PAMPs - β-glucans 
(especially β1,3 and β1,6 glucans), chitin (β1,4-linked polymer of N-acetyl glucosamine) and mannans - are present 
in most aerosolized fungi (all Ascomycetes and Basidiomycetes). Other fungal PAMPs recognized by innate 
immune cells are α-glucans, galactomannans, xylomannans and chitosan, a deacetylated derivative of chitin [26, 27], 
which may be expressed by particular fungal taxa. Whereas α-glucans compose the gel-like polymer of 
Ascomycetes and Basidiomycetes, galactomannans are found in Ascomycetes (principally Aspergillus, but also 
Penicillium and few other species) and xylomannans in Basidiomycetes (e.g. Cryptococcus). Therefore, the 
composition of the cell wall varies significantly between fungal species [28]. 
The immune response to fungal PAMPs is modulated according to fungal PAMPs distribution at the surface of 
fungal particles, their size, shape and linkage to other components. Pathogenic fungi have developed strategies to 
avoid immune recognition, for example Cryptococcus neoformans that bears a capsule, and dormant conidia of 
Aspergillus fumigatus that are covered by an immunologically inert hydrophobic rodlet layer [29]. Moreover, the 
fungal cell wall is a dynamic structure uneven during cell cycle and morphological transition. β1,3-glucans are 
exposed on conidia but masked on hyphae of Candida albicans. By masking immunogenic PAMPs, fungi 
circumvent inflammatory responses, favoring fungal adaptation and opportunism [19].  
The main PRRs involved in the sensing of fungal PAMPS are C-type lectin receptors (CLRs, such as dectin-1, 
dectin-2, mincle, DC-SIGN, the mannose receptor, the mannose binding lectin and galectin-3), Toll-like receptors 
(TLRs, especially TLR2, TLR4 and TLR9) and Nod-like receptors (NLRs) [19, 30-32]. The cooperative recognition 
of fungal PAMPs by several PRRs is required for optimal anti-fungal responses [33-35]. Most of our knowledge 
about PRRs and pathways involved in host responses to fungi derives from studies using mostly the thermophilic 
species C. albicans and A. fumigatus [19, 26, 27, 30-32, 36] and can only be extrapolated to mesophilic species 
when these species are sharing similar cell wall characteristics and cytoplasmic composition.  
β1,3 glucans are the major components of fungal cell wall. Immune cells sense β-glucans primarily through dectin-1 
that is expressed at high levels by myeloid cells, yet with possibly different outcomes. For example, β-glucans 
trigger much higher TNF production by DCs than by macrophages [37]. TLR2, complement receptor 3 (CR3) and 
scavenger receptors (CD5, CD36 and SCARF1) have also been described to detect β-glucans. Ligand binding to 
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dectin-1 engages Syk-CARD9 and Raf-1 dependent signalling pathways that relay activation of the canonical (c-
Rel) and non-canonical (RelB) nuclear factor (NF)-κB pathways, and stimulates endocytosis and phagocytosis, the 
respiratory burst, the production of cytokines and chemokines, the differentiation and maturation of DCs and the 
development of effector T and B cells responses [38-40]. The panel of cytokines produced following dectin-1 
triggering drives antifungal Th1 and Th17 responses. Shaping the development of Th17 responses requires the 
interaction of dectin-1 with TLRs, which amplifies the production of IL-1β, IL-6 and IL-23 and down-regulates the 
production of IL-12 [41]. Interestingly, dectin-1 promotes pro-IL-1β processing via activation of both the canonical, 
caspase-1 dependent, NLRP3 (NLR pyrin domain containing 3) inflammasome and a noncanonical caspase-8 
inflammasome [42, 43]. The density of β1,3 glucans at the cell surface varies between fungal species and between 
fungal forms (yeast or hyphae). Mold-induced asthma in mice repeatedly exposed to Aspergillus versicolor and 
Cladosporium cladosporioides - fungal species with respectively high and low surface β-glucans - revealed that A. 
versicolor induces a dectin-1 dependent Th17 response with neutrophilia and low airway hyper-responsiveness 
(AHR) whereas C. cladosporioides induces a dectin-1 independent Th2 response with eosinophilia and strong AHR 
[44, 45]. These data suggest that fungi that expose low levels of β-glucans at their surface are more susceptible to 
induce allergic Th2 polarized immune responses. In agreement, β-glucans from Wallemia sebi and Eurotium 
amstelodami, fungal species associated to HP development, promote Th1 polarized responses by DCs [20]. Along 
with a primordial role for dectin-1 in antifungal defences, mutations in dectin-1 and CARD9 have been associated 
with fungal infections [46-48]. 
Chitin is the second-most abundant polysaccharide in fungal cell wall. Chitin is not surface-exposed, but chitin 
fragments are released and stimulate host cells following phagocytosis and digestion of fungal particles by lysozyme 
and chitinase/chitinase-like proteins (C/CLPs) that are constitutively expressed by epithelial lung cells and 
macrophages [49]. Moreover, chitin content and exposure at the cell surface may increase upon antifungal therapy 
with echinocandins, and therefore affect host immune responses [50, 51]. Experimental and clinical studies have 
associated dysregulated expression of C/CLPs with Th2 inflammation and asthma development [52]. Like-minded, 
intrapulmonary administration of chitin into mice induced a macrophage-dependent recruitment of IL-4 expressing 
eosinophils and basophils [53]. Interestingly, while both chitin and chitosan are phagocytosed by macrophages, only 
chitosan activates the NLRP3 inflammasome and IL-1β secretion [54]. How the host senses and responds to chitin 
remains to be fully elucidated. Chitin particles promote not only Th2 responses, but also Th1 as well as Th17 
responses [52]. These paradoxical findings likely arise from the usage of chitin preparations differing in origin 
(commercially available chitin is usually extracted from crab/shrimp shells), purity and particle size. Whereas large 
chitin fragments are immunologically inert, chitin particles of 40-70 μm stimulate tumor necrosis factor (TNF) 
through dectin-1 and TLR2 while chitin particles below 40 μm induce TNF and IL-10 through dectin-1, the 
mannose receptor and TLR2 in macrophages [55]. Yet, a recent study using ultra-pure fungal-derived chitin of 1-10 
μm, a size likely to be relevant for host responses, showed that low concentrations of chitin stimulate IL-10 
production while high concentrations of chitin induce predominantly TNF [56]. Intracellular delivery of chitin by 
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the mannose receptor was preceding chitin sensing by TLR9 and NOD2. Thus, one can postulate that protection 
against Aspergillus-driven acute allergic disease afforded by the administration of CpG (a TLR9 agonist) into mice 
might result from binding competition between CpG and chitin to TLR9 [56, 57]. Additional receptors expressed by 
myeloid cells possibly involved in chitin/chitosan recognition encompass the C-type lectins galectin-3 and RegIIIγ, 
FIBCD1 and NKR-P1 [49].  
Mannans are α-linked polymers of mannose covalently attached to fungal cell wall mannoproteins through ester 
linkage (O-linked) or amine bond (N-linked). Mannans are recognized by the mannose receptor (CD206), dectin-2, 
dectin-3, DC-SIGN (CD209), TLR2, TLR4 and possibly mincle [27, 32, 34, 36, 58]. While CLRs recognize N-
branched mannans, TLR4 senses O-branched mannans [33]. TLR4 and TLR2 recognize glucuronoxylomannans 
from C. neoformans and phospholipomannan from C. albicans, respectively [59, 60]. The mannose receptor is 
predominantly expressed by macrophages and DCs as part of the endocytic pathway. The mannose receptor senses 
several fungi and mediates, in collaboration with the TLR2/dectin-1 pathway, the release of a number of cytokines 
among which IL-17 [61]. Dectin-2, expressed by myeloid cells, was the first PRR shown to induce proinflammatory 
cytokine expression in response to fungal hyphae [62, 63]. Indeed, dectin-2 senses α-mannans and induces Th17 
responses [64, 65]. Recently, dectin-2 was shown to form with dectin-3 a heterodimeric complex to recognize α-
mannans and mediate host defenses to C. albicans infection [58]. DC-SIGN expressed on DCs, macrophages and 
endothelial cells favors the uptake and phagocytosis of C. albicans and A. fumigatus conidia, which is inhibited by 
Aspergillus-derived galactomannans [66-68]. The sensing of C. albicans through DC-SIGN modulates co-signaling 
via TLRs and stimulates the production of IL-10, suggesting an important role of mannans in regulating DC 
response [67]. Mincle is predominantly expressed on activated macrophages and detects mannose derivatives or N-
acetyl-glucosamine from C. albicans [69] as well as glycolipids from Malassezia, an opportunistic skin fungal 
pathogen [70, 71]. Interestingly, co-engagement of mincle and dectin-1 by Fonsecaea monophora, an etiologic 
agent of chromoblastomycosis, blocks IL-12 production and redirects dectin-1 mediated antifungal Th1 polarization 
to a Th2 response [72]. 
All these data indicate that fungi trigger multiple PRRs of the same or different families to modulate host immune 
response to their own benefit. Conversely, cross-regulation of cytokine production by immune cells through the 
engagement of multiple PRRs fine-tunes host defense mechanisms, allowing resistance and tolerance to fungi. 
1.3. Fungal allergens 
Fungi express multiple kinds of allergens - cytoplasmic and structural components released upon cell (auto) lysis 
and secreted metabolic products. In contrast to fungal cell wall components, allergens are mostly fungal species or 
family specific. Fungal allergens elicit hypersensitivity reactions not only of type I (IgE-mediated), but also of type 
II, type III (IgG-mediated) and type IV (delayed type hypersensitivity) that may act together to mediate 
pathogenesis. Yet, fungi are poorly studied in the field of molecular allergology, and the role of fungal allergens in 
airway diseases is poorly characterized [73]. Fungal allergenic proteins, secreted mainly during spore germination 
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and mycelia growth, can be classified into five chief categories: proteases, glycosidases, components of protein 
synthesis/secretion, proteins of the stress response and proteins of gluconeogenesis. Fungal proteases have been 
characterized in some fungal species relevant for allergic respiratory diseases, such as A. fumigatus (Asp f5, f6, f11, 
f13, f15, f18) and Trichophyton rubrum (Tri r4, Tri t4). Fungal proteases play a particularly important role in 
allergen sensitization, and represent one of the initiator of lung allergic responses [7, 74]. Indeed, proteases initiate 
Th2-skewed lung allergenic responses by inducing thymic stromal lymphopoietin (TSLP) secretion by lung 
epithelial cells [75]. Proteases may have also an adjuvant effect on allergenic properties of other proteins [7]. 
Proteases facilitate antigen access to host cells by direct receptor-specific interaction involving protease-activated 
receptor type-2 (PAR-2) with epithelial cells or by damaging epithelial cells allowing access to underlying cells. As 
an example, A. alternata, A. fumigatus and Cladosporium herbarum proteases not only stimulate cytokine secretion, 
but also promote epithelial cell barrier disruption [76, 77]. A. alternata extracts also activate eosinophils in a PAR-2-
dependent manner, favoring allergen sensitization and Th2-biased inflammatory responses [78, 79].  
1.4. Fungal metabolites 
1.4.1. Non-volatiles low molecular weight metabolites: mycotoxins 
Mycotoxins are secondary metabolites produced by a large number of Ascomycetes at particular stages of fungal 
growth and in particular environments. They are rarely specific of one fungal species and they are most frequently 
produced by close related fungal species. However, within the same species, some strains are mycotoxins producers 
and others not. As they are present within fungal particles, mycotoxins can be inhaled at the same time as fungal 
particles. Mycotoxins produced by Aspergillus, Penicillium, Stachybotrys, Trichoderma and Chaetomium species 
have been detected indoor [80], whereas those produced by Aspergillus, Fusarium or Penicillium species have been 
found in the aerosols of occupational places where plant derived materiel is manipulated. Only the mycotoxins 
produced by Aspergillus, Fusarium and Penicillium species (Table 1) have been classified as carcinogenic in 
humans and animals [81]. In addition to their toxic effects, mycotoxins may also display important 
immunomodulatory and immunotoxic effects depending on toxin concentration, toxin co-administration and the 
ratio between each toxin. Aflatoxin and ochratoxin suppress cell-mediated immunity [82]. Gliotoxin, patulin and 
citrinin impair IFNγ production [83] and decrease intracellular glutathione in DCs, which is responsible for 
decreased IL-12 secretion and skewing toward Th2 immune responses [84]. Trichothecene mycotoxins (T-2 toxin, 
nivalenol, deoxynivalenol, 3-acetyldeoxynivalenol, fusarenon-X) have strong immunotoxicity as these toxins target 
mitotic tissues with important immune functions such as the bone marrow, intestinal mucosa, lymph nodes and 
thymus. While trichothecene mycotoxins are usually considered immunosuppressive, one of them, deoxynivalenol, 
may either stimulate or suppress immune functions depending on the dose and exposure conditions [85]. The 
estrogenic mycotoxin zearalenone (ZEA) and its metabolites bind the estrogenic receptor to inhibit immune 
functions such as cytokine production (TNF, IL-1β, IL-6, IL-8 and IFNγ) and T cell proliferation [86, 87]. 
Fumonisin B1 have animal species-specific effects, thus the immunosuppressive activities attributed to this 
mycotoxin in pigs are not necessarily extrapolated to humans [82, 88].  
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1.4.2. Volatiles low molecular weight metabolites: microbial volatile organic components 
All molds produce volatile organic components (VOCs). More than 200 different microbial VOCs (MVOCs) have 
been characterized in fungi, mostly alcohols, aldehydes, amines, chlorinated hydrocarbons, ketones, terpenes, 
aromatic and sulphuric compounds [89, 90]. MVOCs are often responsible of strong/unpleasant odors. Fungi have 
unique MVOC profiles depending on their development stage, size and substrate for development. For example, 1,3-
dimethoxybenzene and 2,4-pentandione are produced by A. versicolor and A. fumigatus but not Penicillium 
expansum, Penicillium chrysogenum, Aspergillus niger and C. cladosporoides growing on wall paper [91]. Chronic 
exposure to MVOCs may lead to short as well as long term adverse health effects. In the airways of sensitive people, 
MVOCs induce irritation and inflammation [89, 90]. In agreement, two prevailing MVOCs, α-pinene and 1-octen-3-
ol, stimulate cytokine and nitric oxide production by immune cells (neutrophils and alveolar macrophages; 
hemocytes in Drosophila) [92]. Of note, some fungi produce both mycotoxins and MVOCs (Aspergillus and 
Penicillium spp.; Table 1), which may further affect the sensitive host. Yet, clearly much more work is required to 
fully appreciate the immunomodulatry properties of mycotoxins and MVOCs and their impact in human airway 
diseases. 
2. Allergic responses after fungal particle exposure 
2.1. Allergic asthma 
Asthma is a multifactorial chronic and persistent pulmonary inflammation with airway obstruction, breathlessness, 
mucus hyper-secretion and airway hyper-responsiveness, clinically ranging from intermittent to severe forms [93, 
94]. Inflammation leads to bronchoconstriction, vasodilatation and hyperplasia of bronchial smooth muscles. The 
prevalence of mold allergy to Alternaria, Aspergillus, Candida, Cladosporium and Penicillium is much higher in 
atopics and asthmatics when compared to the general population [73]. Moreover, numerous epidemiological studies 
have associated chronic exposure to fungi with asthma symptoms in children and asthma exacerbation in adults [4, 
6, 80, 95, 96]. The most frequent fungal species associated with allergic asthma are Alternaria, Aspergillus, 
Aureobasidium, Cladosporium, Epicoccum, Helminthosporium and Penicillium [97]. Bronchial provocation tests 
with spores in non-occupational mild asthmatic adult patients suggest that a minimal dose of 9.104 spores of A. 
alternata and 6.104 spores of Penicillium spp. is required to induce clinical symptoms [98]. To distinguish fungal 
sensitization from fungal involvement in asthma development and/or exacerbation, allergen-specific IgE serum 
levels should be systematically tittered for a large panel of fungal allergens, together with a systemic analysis of the 
dominant fungal species to which asthmatic subjects are exposed. 
Etiologic agents associated with asthma of fungal origin are heterogeneous, and a role for fungal chitin and 
proteases as triggered of asthmatic reactions has been proposed [7]. As discussed earlier, fungi with low or 
unavailable cell surface β-glucans favor Th2 polarized immune response related to an asthmatic phenotype. In 
addition, mycotoxins such as gliotoxin and patulin impact on DCs to stimulate Th2 responses and trigger asthma-
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like symptoms in a model of acute asthma in mice [84]. The underlying mechanisms involved in allergic airway 
diseases are not fully understood, but our knowledge has improved markedly over the last years. Allergens activate 
airway epithelial cells and DCs to produce IL-1, IL-25, IL-33, TSLP, GM-CSF, eicosanoids and danger signals that 
are involved in the expansion and activation of type 2 innate lymphoid cells (ILC2) and activate DCs migration to 
lymph nodes where they instruct Th2 cell differentiation with the help of IL-4 secreting basophils [99, 100]. Lung 
ILC2 are a major source of IL-5, IL-9 and IL-13 that, with other cytokines from the local milieu, induce 
eosinophilia, mast cell mobilization and IgE and mucus production. Of note, ILC2 have just been reported to be 
increased in the blood of asthmatic patients [101], but not yet in asthmatic lung tissues contrary to IL-25, IL-33 and 
TSLP. Asthma has long been considered as a Th2-mediated pathology, but recently Th17 cells have been pointed 
out as important effector cells in asthma, especially severe steroid-resistant asthma characterized by IL-17 
production and neutrophilia [102]. Th17 differentiation is dictated by DCs secreting IL-1β and IL-23, and associated 
with the expression of IL-17 and IL-22, a member of the IL-10 family that can mediate both pro-inflammatory and 
anti-inflammatory effects [103]. Overall, the phenotypic heterogeneity of asthma might be related to T cell response 
polarization. Yet, the underlying mechanisms responsible for dominant Th2, Th17 or Th2/Th17 mixed responses 
during allergic asthma are not well understood. 
2.2. Allergic bronchopulmonary aspergillosis (ABPA) and allergic bronchopulmonary mycosis (ABPM)  
ABPA refers to an exaggerated immune response to fungal colonization of the lower airways by A. fumigatus 
whereas ABPM refers to allergic bronchopulmonary diseases due to species other than Aspergillus. The principal 
etiological agents of ABPM reported worldwide are C. albicans, Bipolaris spp., Schizophyllum commune and 
Curvularia spp. [104]. ABPM/ABPA prevalence in the general population is unknown. ABPA prevalence in 
patients having mucociliary clearance impairment such as asthmatic and cystic fibrosis patients is around 1-2% and 
2-15%, respectively [105, 106]. The prevalence of ABPM in asthmatic and cystic fibrosis patients is unknown, yet 
ABPM occurs more frequently than ABPA in patients without asthma [104]. The exposure level of spores triggering 
ABPA/ABPM is not clearly defined. Due to impaired mucociliary clearance, fungal particles from thermophilic 
species might remain in the lower respiratory tract long enough to germinate and to breach the epithelial barrier. 
This may lead to pro-inflammatory cytokine release, activation of antigen presentation cells and skewed Th2 
responses with mast cell proliferation and eosinophilia [104, 107]. ABPA/ABPM are characterized by severe asthma 
initially associated with type I IgE-mediated hypersensitivity, subsequently with type III IgG-mediated 
hypersensitivity [104]. Type IV hypersensitivity is also present in ABPA. Fungal specific IgE, IgA and IgG can be 
detected in bronchoalveolar lavage  and serum of patients [104]. The diagnosis of ABPA/ABPM is not trivial, and 
the identification of genetic risk factors should improve the recognition of high-risk patients (Table 2). It seems also 
important to enlarge the panel of fungi tested for ABPM diagnosis. 
2.3. Allergic fungal rhinosinusitis (AFRS)  
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Although the definition of AFRS is controversial, AFRS can be described as a subset of chronic rhinosinusitis 
(CRS) in immunocompetent patients due to fungal colonization of a sinus with impaired mucociliary clearance [108-
110]. AFRS patients generally suffer from a unilateral chronic sinus infection with fungal allergy, nasal airway 
obstruction and congestion, purulent rhinorrhoea, postnasal drainage and headache [109]. Eosinophilic mucus, 
fungal detection in sinus, presence of nasal polypsis and type I IgE-mediated hypersensitivity are characteristics of 
AFRS patients [111]. Symptoms associated with AFRS are related to luminal degranulation of mucosal eosinophils 
and release of cytotoxic proteins (Charcot-Leyden crystals) responsible of tissue damages [112]. Aspergillus species 
were expected to be a common causative agent of AFRS, however Bipolaris spicifera, Curvularia lunata, A. 
alternata, Cladosporium spp. and Trichoderma longibrachiatum are commonly incriminated in AFRS [109, 113-
115]. Unexplained cases of CRS should be systematically screened for AFRS diagnostic since allergic fungal 
sinusitis represent 6 to 9 % of the CRS requiring surgery [116].  
The prevalence of AFRS is higher in warm geographical regions with a high humidity rate (from 0 to 23% in USA) 
[117]. AFRS prevalence ranges from 5 to 10% in CRS patients, and AFRS patients can represent more than 87% of 
the patients with fungal rhinosinusitis (FRS) [118]. Controversy on the classification of CRS and difficulties of 
differential diagnosis between CRS subcategories may explain the absence of a fair description of the 
immunological cascade underlying AFRS pathogenesis. AFRS is characterized by mixed type I, III and IV 
hypersensitivity reactions, and T cell-derived IL-5 and IL-13 that activate eosinophils to release toxic factors for the 
epithelium in the sinus cavity. Interestingly enough, CRS was the first human pathology in which the accumulation 
of ILC2 in inflamed tissues was clearly shown [119]. Although allergic rhinitis is classically viewed as a Th2 
skewed pathology, recent studies have shown the up-regulation of Th17 specific parameters in local mucosa and 
peripheral blood of patients, which correlated with eosinophilia and symptom severity [24]. 
2.4. Hypersensitivity pneumonitis (HP) 
HP, also called extrinsic allergic alveolitis, is a generic term defining a non IgE-mediated bronchial and alveolar 
inflammation caused by an exaggerated immunological response to a variety of organic particles. The most common 
antigens implicated in HP are bird proteins and bacteria; however fungi are also frequently incriminated in HP 
development in particular working populations and in the general population in Japan [120]. Acute HP patients 
suffer from fever, chills, dyspnea, dry cough, headache, malaise, interstitial mononuclear cell infiltration, non-
necrotizing poorly formed granulomas, cellular bronchiolitis with spontaneous resolution after cessation of antigen 
exposure. Chronic HP patients also have chronic interstitial inflammation and alveolar destruction associated with 
dense fibrosis in 41% of the cases [3, 98]. The prevalence of HP in the general population is low (around 0.9 cases 
per 100’000/year in the United Kingdom) but much more elevated in populations chronically exposed to high 
amounts of fungal particles such as farmer’s population [3, 121, 122]. Provocation tests suggest that repeated 
exposure to 107 to 4.109 spores/m3 is required to set off fungal-related HP [98]. 
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HP subtypes are classically defined based on the nature of inhaled antigens, the most common being the bird 
fancier’s lung and the farmer’s lung. The panel of fungi involved in HP is large (for example Aspergillus, 
Alternaria, Aureobasidium, Cladosporium, Cryptococcus, Epicoccum, Eurotium amstelodami, Fusarium, 
Lichtheimia , Paecilomyces, Penicillium, Trichosporon and Wallemia), reflecting the population and geographical 
area of interest [3, 123].  
HP is a mix of type III and type IV allergic reaction. The immune response is characterized by neutrophilic and 
lymphocytic infiltration in the lower respiratory tract with macrophage and T cell-derived cytokines. In acute and 
subacute clinical forms, cell-mediated immunopathogenesis has been associated with Th1 responses [124]. 
However, Th2 mechanisms have been described in chronic HP with a fibrotic phenotype [125]. In addition, mouse 
models of Stachybotrys chartarum-induced HP suggest that Th17 responses are also involved in HP pathogenesis 
[126]. 
3. Non-allergic disease to fungal compounds 
3.1. Chronic bronchitis 
Chronic bronchitis refers to a recurrent, often irreversible, inflammation of the bronchial mucous membrane with 
hypersecretion of mucus and hyperplasia of goblet cells and submucosal glands. Its prevalence in the general 
population is around 2.5% but can vary from 5 to 40% among workers depending on the level of exposure to 
antigens [98]. Chronic bronchitis occurs after long-term exposure to large concentrations of fungal spores (2.109 to 
14.109 spores/m3 over 1 hour) resulting in irreversible damages to the lung. Predominant clinical symptoms are a 
persistent wet cough and breathing complications [98]. A. fumigatus and Penicillium frequentans (present on cork) 
are associated with chronic bronchitis [127, 128]. Our understanding of the pathophysiology of chronic bronchitis is 
rudimentary. 
3.2. Organic dust toxic syndrome (ODTS) 
ODTS is also known as toxic alveolitis, pulmonary mycotoxicosis, silo unloader’s (filler’s) syndrome, atypical 
farmer’s lung or grain fever. ODTS is an acute, non-allergic sickness characterized by flu-like symptoms associated 
with a local acute toxic effect due to exposure to very high amounts of organic dust [9]. In most cases, symptoms 
(cough, fever, breathlessness) develop 4 to 8 hours after exposure. Symptoms last generally less than 24 hours but 
may persist 5-7 days [9]. The prevalence of ODTS is around 36% among workers exposed to organic dusts; it is 
unknown in the general population [129]. Due to the increased protection of agricultural workers, ODTS cases are 
expected to decrease in the future. ODTS is related to inhalation of mycotoxins during mold contaminated grain 
handling (coffee, pepper, wheat) or animal (e.g. poultry) related activities. The principal fungal species incriminated 
are A. fumigatus, Aspergillus nidulans and Penicillium spp. [130]. The exact role of mycotoxins in ODTS is not 
clearly defined, yet adverse events are more related to chronic exposure to toxicogenic fungi than non-toxicogenic 
fungi [131]. Organic dust inhalation results in massive neutrophil recruitment to the lungs, following chemotactic 
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signals provided by lung epithelial cells and macrophages. Pyrogenic cytokines are likely contributing to fever and 
other inflammatory parameters of ODTS [132]. 
3.3. Chronic mycotoxicosis and other pathologies associated with fungal metabolites 
Water-damage building syndrome, also called “mold-related illness”, has been associated to the exposure to molds 
in water-damaged building. Main symptoms are fatigue, headache with dermatological, gastrointestinal as well as 
reproductive, rheumatologic and immune related symptoms [133]. A wide range of molds is found in water-damage 
buildings, among which Penicillium, Aspergilus, Chaetomium, Acremonium, Ulocladium, Cladosporium, Mucor, 
Trichoderma, Alternaria, Sporothrix, Rhodotorula, Rhizopus, Stachybotrys, Calcarisporium, Scopulariopsis and 
Fusarium spp. to cite the most  representative ones [134]. 
Living and/or working in a water-damage building has been associated with the presence of toxicogenic fungi and of 
their mycotoxins (especially aflatoxin, ochratoxin and trichothecenes) in nasal wash and with an increased 
concentration of mycotoxins in urine [135, 136]. Mycotoxin toxicity may be aggravated by the formation of fungal 
biofilm in sinus [137]. Mycotoxins have also been shown to accumulate in lungs, spleen and lymph nodes [135], as 
well as in placenta, umbilical cord blood and breast milk in symptomatic pregnant women, which might be 
responsible for side effects on fetus or new-born [138]. Despite the established deletary role of mycotoxins in animal 
models, epidemiological evidences struggle to establish a link between mycotoxins and respiratory health effects. 
Intra-tracheal instillation in rats of toxicogenic S. chartarum, a mold suspected to be the etiological agent of 
pulmonary hemorrhages in children due to its presence in the building and in air samples, induces lung inflammation 
related to the release of IL-1β and TNF by β-glucan-activated alveolar macrophages [139]. 
Since MVOCs accumulate in the air of water-damage buildings, they are suspected to participate to health adverse 
events. Exposure to MVOCs has been linked to symptoms such as headaches, nasal irritation, dizziness, fatigue, 
nausea and swelling/inflammation of the airways [140-142]. MVOCs such as 3-methylfuran were also associated 
with other respiratory adverse events summarized in the guidelines for indoor air quality [143]. 
4. Genetic variants as risk factors of fungal non-invasive related pathologies 
Host genetic factors impact on host tolerance or resistance to microorganisms, as it is the case for its susceptibility to 
infection by opportunistic or non-invasive fungal infections. Both primary immune-deficiencies affecting a single 
gene at the individual level (monogenic inheritance) and genetic polymorphisms affecting several genes at the 
population level (polygenic inheritance) have been extensively studied in relation with invasive Aspergillus and 
Candida infections. These studies have implicated polymorphisms in numerous genes encoding for proteins 
involved in the whole immunological cascade activated upon fungal contact, such as PRRs, cytokines, chemokines 
and their receptors and signaling molecules [144, 145]. The most reliable associations, supported by functional 
effects, concern polymorphisms affecting pathways triggered by dectin-1 and pentraxin-3 (PTX3), a PRR involved 
in host defenses against A. fumigatus [146]. Unfortunately, numerous associations may not be robust due to several 
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limitations in study design [145]. This is also true for gene association studies concerning the pathologies discussed 
here, which moreover do not specifically incriminate fungi as the etiological agents of the studied patients apart 
from ABPA and AFRS. This being said, polymorphisms of human leukocyte antigen (HLA) genes have been 
associated with the development of allergic airway disorders (asthma, ABPA/ABPM, AFRS; Table 2). Additionally, 
mutations in IL4RA have been associated with Alternaria-sensitive moderate-severe asthma in children [158], 
whereas mutations in TLR9, CFTR, SPA2, IL4RA and IL10 genes have been reported as risk factors for ABPA [147-
150]. No other unambiguous or validated genetic association with allergic or non-allergic fungal airway disease has 
been reported.  
5. Conclusion 
Although it is well recognized that ubiquitous fungi are involved in the pathogenesis of a broad panel of allergic and 
non-allergic airway diseases, many issues should deserve more attention, for example the molecular characterization 
of fungal allergens in mesophilic fungal species, the screening for fungal allergy in relation with the identification of 
fungal species present in patient environment and the determination of the immunomodulatory or immunotoxic 
effects of mycotoxins and/or MVOCs delivered by these environmental fungal species. Moreover, the mechanisms 
controlling host responses to fungal particles and genetic susceptibility to respiratory pathologies induced by fungi 
were studied primarily in the context of fungal infections such as those promoted by C. albicans and A. fumigatus, 
while mesophilic species associated to the development of allergic or non-allergic  airway diseases receive a much 
more modest attention. In depth characterization of the genetic, molecular and cellular actors involved in host-
mesophilic fungus interactions, of the impact of lung microbial ecosystem on lung immunity and of the 
pathophysiological characteristics of patients with non-invasive airway diseases is also warranted as it would help to 
understand how different fungal species (and microorganisms at large) induce similar pathologies and, conversely, 
how the same fungal species can cause different pathologies. On the long term, answering these questions would 
pave the path for designing new therapeutic strategies with the aim to improve the outcome of patients suffering 
from life threatening airway diseases. 
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Table 1. Fungal families producing mycotoxins and microbial volatile organic components (MVOCs).   
 
Fungal family Mycotoxin MVOCs Reference 
Aspergillus  Aflatoxin, citrinin, gliotoxin, ochratoxin, patulin Yes  [151] 
Fusarium  Deoxynivalenol [DON], 3-acetyl deoxynivalenol [3-ADON], 
fumonisin B1 [FB-1], fusarenon-X, nivalenol [NIV], T-2 toxin, 
zearalenone [ZEA] 
 [152-154] 
Penicillium  Citrinin, gliotoxin, ochratoxin, patulin  Yes  [83, 84, 155] 
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Table 2. Main characteristics of allergic and non-allergic airway diseases associated with an exposure to airborne fungi 1 
 2 
Allergic / 
non allergic 
Pathology Hypersensitivity 
reaction 
Ig response Cellular response Principal fungus Genetic risk factors 
Allergic Asthma Type I 
 
IgE (atopic 
asthma); non-
IgE (nonatopic 
asthma) 
Th2 with eosinophilia 
[156]; Th17 with 
neutrophilia [102, 
157] 
Alternaria, Aspergillus, Aureobasidium, 
Cladosporium, Epicoccum, 
Helminthosporium and Penicillium [97] 
IL4RA and HLA-DQ in children of mixed 
ethnicity with Alternaria –sensitive asthma 
[158] 
 ABPA/ABPM Type I, III, IV IgE  and/or IgG, 
IgA 
Th2, eosinophilia, T 
cells [104, 107] 
A. fumigatus, C. albicans, Bipolaris 
spp., Shyzophyllum commune, 
Curvularia spp. [104] 
HLA-DR, HLA-DQ, IL4RA, IL10 and 
TLR9 in mixed populations from USA, 
France and Germany and UK; SPA2 and 
CFTR in Caucasians [107, 147-150] 
 AFRS Type I IgE Th2 with eosinophilia  
[159] (Th17) [24] 
Aspergillus spp., Bipolaris spicifera, 
Curvularia lunata, A. alternata, 
Cladosporium spp., Trichoderma 
longibrachiatum [109, 113-115] 
HLA-DQ in Hispanic and White Americans 
[160] 
 HP Type III, IV IgG Th1 (acute, subacute), 
Th2 (chronic) and 
Th17 (mouse model), 
neutrophilia, 
lymphocytosis [124 , 
125, 126, 161] 
Aspergillus, Alternaria, Aureobasidium, 
Cladosporium, Cryptococcus, 
Epicoccum, Eurotium amstelodami, 
Fusarium, Lichtheimia corymbifera, 
Paecilomyces, Penicillium, 
Trichosporon, Wallebia sebi [162, 163] 
1 
Non allergic Chronic bronchitis   Neutrophilia [164] A. fumigatus, P. frequentans [127, 128] 1 
 ODTS   Neutrophilia, 
cytokines  [132, 165] 
A. fumigatus, Penicillium spp., A. 
nidulans [130] 
1 
 Chronic 
mycotoxicosis  
  Cytokines [139] Penicillium, Aspergilus, Chaetomium, 
Acremonium, Ulocladiums, 
Cladosporium, Mucor, Trichoderma, 
Alternaria, Sporothrix, Rhodotorula, 
Rhizopus, Stachybotrys, 
Calcarisporium, Scopulariopsis and 
Fusarium spp. [131, 134] 
1 
1 No unambiguous association reported 3 
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